CPI-203
CPI-203 is a novel potent, selective and cell permeable inhibitor of BET bromodomain, with an IC50 value of appr 37 nM (BRD4 α-screen assay) .
Product Specifications
CAS Number
1446144-04-2
UNSPSC
12352005
Hazard Statement
H302, H315, H319, H335
Target
Apoptosis; Epigenetic Reader Domain
Type
Reference compound
Related Pathways
Apoptosis; Epigenetics
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/cpi-203.html
Concentration
10mM
Purity
99.03
Solubility
DMSO : ≥ 47 mg/mL
Smiles
ClC1=CC=C(C(C2=C(N3C4=NN=C3C)SC(C)=C2C)=N[C@H]4CC(N)=O)C=C1
Molecular Formula
C19H18ClN5OS
Molecular Weight
399.90
Precautions
H302, H315, H319, H335
References & Citations
[1]Devaiah BN, et al. BRD4 is an atypical kinase that phosphorylates serine2 of the RNA polymerase II carboxy-terminal domain. Proc Natl Acad Sci U S A. 2012 May 1;109 (18) :6927-32.|[2]Moros A, et al. Synergistic antitumor activity of lenalidomide with the BET bromodomain inhibitor CPI203 in bortezomib-resistant mantle cell lymphoma. Leukemia. 2014 Oct;28 (10) :2049-59
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
HA723173 100 µL
Acetylated-Lysine Recombinant Rabbit multiclonal Antibody
Sign In for Pricing
View Details 
